MX9207654A - Composicion tiroactiva de liberacion sostenida. - Google Patents

Composicion tiroactiva de liberacion sostenida.

Info

Publication number
MX9207654A
MX9207654A MX9207654A MX9207654A MX9207654A MX 9207654 A MX9207654 A MX 9207654A MX 9207654 A MX9207654 A MX 9207654A MX 9207654 A MX9207654 A MX 9207654A MX 9207654 A MX9207654 A MX 9207654A
Authority
MX
Mexico
Prior art keywords
liothyronine
thyroxine
sustained release
useful
disclosed
Prior art date
Application number
MX9207654A
Other languages
English (en)
Inventor
Eric Paul Krenning
Georg Hennemann
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of MX9207654A publication Critical patent/MX9207654A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Abstract

Se describen formas de dosificación de liberación sostenida de liotironina, en combinación con liberación normal o sostenida de tiroxina, en una relación molar de aproximadamente 1 a 50:1, especialmente de 5 a 20:1, útiles en la terapia de reemplazo de hormona tiroide, sorprendentemente, se descubre que mediante la incorporación de liotironína, y opcionalmente tiroxina, en una forma de dosificación de acción prolongada en las relaciones descritas.
MX9207654A 1991-12-30 1992-12-30 Composicion tiroactiva de liberacion sostenida. MX9207654A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91203438 1991-12-30

Publications (1)

Publication Number Publication Date
MX9207654A true MX9207654A (es) 1994-05-31

Family

ID=8208120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9207654A MX9207654A (es) 1991-12-30 1992-12-30 Composicion tiroactiva de liberacion sostenida.

Country Status (14)

Country Link
US (1) US5324522A (es)
EP (1) EP0550108B1 (es)
JP (1) JP3662942B2 (es)
KR (1) KR100249978B1 (es)
AT (1) ATE164063T1 (es)
AU (1) AU660344B2 (es)
CA (1) CA2086343C (es)
DE (1) DE69224809T2 (es)
DK (1) DK0550108T3 (es)
ES (1) ES2115638T3 (es)
MX (1) MX9207654A (es)
NO (1) NO924985L (es)
NZ (1) NZ245575A (es)
ZA (1) ZA9210059B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401892D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
GB9401879D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
EP0861073B1 (en) * 1995-11-14 2004-07-28 Abbott GmbH & Co. KG Stabilized thyroid hormone preparations and methods of making same
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
WO1999043307A1 (en) * 1998-02-26 1999-09-02 Prange Arthur J Jr Thyroid hormone replacement using sustained release triiodothyronine
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6740680B1 (en) * 1999-04-26 2004-05-25 Becton Pharma, Inc. Pharmaceutical compositions to tetrac and methods of use thereof
ES2265939T3 (es) * 1999-04-26 2007-03-01 Elliot Danforth, Jr. Composiciones farmaceuticas de tetrac y procedimiento para su utilizacion.
US6288117B1 (en) * 2000-03-23 2001-09-11 North Shore-Long Island Jewish Research Institute Method for treating congestive heart failure
AU2001278034A1 (en) * 2000-07-26 2002-02-05 Bio-Diagnostics Inc. Method for diagnosing thyroid conditions and for monitoring thyroxine therapy
US7163918B2 (en) * 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US7067148B2 (en) * 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030194437A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Cmax properties
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20040043066A1 (en) * 2001-10-29 2004-03-04 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
MXPA04006017A (es) * 2001-12-20 2005-06-08 Femmepharma Inc Suministro de farmacos por via vaginal.
WO2004041208A2 (en) * 2002-11-05 2004-05-21 New River Pharmaceuticals Inc. Controlled absorption of mixed thyroyd hormone formulations
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
JP2006515026A (ja) * 2003-01-02 2006-05-18 フェムファーマ ホールディング カンパニー， インコーポレイテッド 乳房の疾患および障害の処置のための薬学的調製物
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20040156893A1 (en) * 2003-02-11 2004-08-12 Irwin Klein Method for treating hypothyroidism
US8293272B2 (en) * 2003-05-02 2012-10-23 Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H. Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
CA2546601A1 (en) * 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
AU2006230557A1 (en) * 2005-03-31 2006-10-05 King Pharmaceuticals Research & Development, Inc. Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
EP1898926A2 (en) 2005-05-26 2008-03-19 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
AU2006249348B2 (en) * 2005-05-26 2012-05-24 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
GB0608402D0 (en) * 2006-04-28 2006-06-07 Diurnal Ltd Thyroid treatment
US8394921B2 (en) 2006-07-25 2013-03-12 Lipoxen Technologies Limited N-terminal derivatisation of proteins with polysaccharides
CA2674078C (en) * 2006-12-26 2012-03-20 Femmepharma Holding Company, Inc. Topical administration of danazol
EP2148660A2 (en) * 2007-04-23 2010-02-03 Diurnal Ltd Sustained release
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
CA2805958A1 (en) * 2009-08-04 2011-02-10 Haren Treasurer Greater utility with thyroid hormone
EP2441450B1 (en) * 2010-10-18 2017-06-14 Blymum S.R.L. Antioxidant composition for reducing the oxidative stress and side effects ascribable to treatment with levothyroxine
EP3260443B1 (en) * 2011-04-08 2020-10-07 Bracco Imaging SPA A pharmaceutical composition comprising a sulfated derivative of 3,5-diiodo-o-[3-iodophenyl]-l-tyrosine
US20130005814A1 (en) * 2011-07-01 2013-01-03 Thomas Najarian Methods and compositions for facilitating weight loss by administration of thyroid hormones
US10188739B2 (en) 2014-02-27 2019-01-29 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
US20180064669A1 (en) * 2016-05-03 2018-03-08 Spectrix Therapeutics, LLC Compositions and methods of providing thyroid hormone or analogs thereof
KR20210154264A (ko) * 2016-05-03 2021-12-20 스펙트릭스 테라퓨틱스, 엘엘씨 갑상샘 호르몬 또는 이의 유사체를 제공하는 조성물 및 방법
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US10695309B2 (en) 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB219206A (en) * 1923-09-15 1924-07-24 John Arthur Goodall Improvements in extincteurs or apparatus for use in the extinguishing of fires
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
GB1047082A (en) * 1963-02-01 1966-11-02 Pfizer & Co C Thyronine derivatives
NL297631A (es) * 1963-06-03
US3577535A (en) * 1966-06-29 1971-05-04 Armour Pharma Treatment of thyroid hormone impairment pharmaceutical compositions containing 3,5,3' -l-triiodothyronine complexes
US3477954A (en) * 1966-06-29 1969-11-11 Armour Pharma Phosphonium iodide complexes of thyroxine,methods of preparing same,and methods of preparing 3,5,3'-l-triiodothyronine therefrom
US3689669A (en) * 1970-10-09 1972-09-05 Univ Of North Carolina The Antidepressant method and composition
US3928553A (en) * 1972-03-23 1975-12-23 Univ New York Radioimmunoassay method for triiodothyronine and thyroxine
US4012498A (en) * 1974-03-27 1977-03-15 Sandoz, Inc. Sustained release tablet formulations
US3939259A (en) * 1974-05-24 1976-02-17 Anthony Pescetti Coating composition and therapeutic preparation incorporating same
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
EP0162492B1 (en) * 1984-04-11 1989-08-02 Thiemann Arzneimittel GmbH Dosage units for controlled release of active material
CN1011118B (zh) * 1986-06-13 1991-01-09 天津医学院附属医院 治疗白内障的眼药水的制药方法
US4970075A (en) * 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations

Also Published As

Publication number Publication date
US5324522A (en) 1994-06-28
ATE164063T1 (de) 1998-04-15
NO924985D0 (no) 1992-12-22
KR100249978B1 (ko) 2000-04-01
ZA9210059B (en) 1993-08-03
NO924985L (no) 1993-07-01
EP0550108A1 (en) 1993-07-07
AU660344B2 (en) 1995-06-22
NZ245575A (en) 1995-03-28
CA2086343C (en) 2004-03-09
DK0550108T3 (da) 1999-01-04
CA2086343A1 (en) 1993-07-01
JP3662942B2 (ja) 2005-06-22
ES2115638T3 (es) 1998-07-01
DE69224809T2 (de) 1998-07-09
DE69224809D1 (de) 1998-04-23
AU3044492A (en) 1993-07-01
JPH05255081A (ja) 1993-10-05
EP0550108B1 (en) 1998-03-18

Similar Documents

Publication Publication Date Title
MX9207654A (es) Composicion tiroactiva de liberacion sostenida.
GB8623557D0 (en) Therapeutic agents
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
PT85591A (en) Process for the preparation of multiple unit dosage pharmaceutical compositions comprising as a pharmaceutilly active compound l-dopa
EP0911331A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
EE03089B1 (et) Ibuprofeeni sisaldav kihisev ravimpreparaat ja selle valmistamise meetod
ATE97572T1 (de) Azelastin enthaltende arzneimittel mit kontrollierter wirkstoffabgabe.
KR970009583B1 (en) Calcium supplements
NZ332655A (en) Pharmaceutical compositions containing diclofenac and alkali metal bicarbonates
SE9301112D0 (sv) A new composition
DE2963545D1 (en) Pharmaceutical composition containing all-e- or 13-z-7,8-dehydro-retinoic acid and process for its preparation
GB2258397A (en) Pharmaceutical compositions containing amethocaine
EP0335446A3 (en) Agents for treating neoplasms
TH15493A (th) สารผสมกระตุ้นต่อมธัยรอยด์ชนิดให้ตัวยาออกมาอย่างช้าๆ เป็นระยะเวลานาน
TH9910B (th) สารผสมกระตุ้นต่อมธัยรอยด์ชนิดให้ตัวยาออกมาอย่างช้าๆ เป็นระยะเวลานาน
GR3031360T3 (en) Composition based on ibuprofen, for oral usage
IT1242026B (it) Composizione farmaceutica contenente un complesso ferro-schizokinene per il trattamento dell'anemia ferropenica.